Olmesta
Generic Name
Olmesartan Medoxomil
Manufacturer
Incepta Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| olmesta 10 mg tablet | ৳ 6.00 | ৳ 60.00 |
Description
Overview of the medicine
Olmesta 10 mg Tablet contains Olmesartan Medoxomil, an Angiotensin II Receptor Blocker (ARB) used to treat high blood pressure (hypertension). It works by relaxing blood vessels, allowing blood to flow more easily and reducing the workload on the heart.
Uses & Indications
Dosage
Adults
The usual recommended starting dose is 20 mg once daily. The dose can be increased to 40 mg once daily if blood pressure is not adequately controlled. For Olmesa 10 mg, it may be used as initial dose for specific patients or for dose titration.
Elderly
No initial dose adjustment is generally necessary, but careful monitoring is advised, especially in patients over 75 years of age. Some may require a lower starting dose.
Renal_impairment
No initial dose adjustment is needed for mild to moderate renal impairment. For severe renal impairment (creatinine clearance < 20 mL/min), a lower starting dose (e.g., 10 mg once daily) and careful monitoring are recommended. Not recommended for patients on dialysis.
How to Take
Olmesta 10 mg Tablet should be taken orally, once daily, with or without food. It is recommended to take the tablet at approximately the same time each day to maintain consistent blood pressure control.
Mechanism of Action
Olmesartan Medoxomil is a prodrug that is rapidly converted to its active metabolite, olmesartan, in the gastrointestinal tract. Olmesartan selectively blocks the binding of angiotensin II to the AT1 receptor found in many tissues (e.g., vascular smooth muscle, adrenal gland). This blockade inhibits the vasoconstrictive and aldosterone-secreting effects of angiotensin II, leading to vasodilation, reduced peripheral resistance, and subsequently, a decrease in blood pressure.
Pharmacokinetics
Onset
Antihypertensive effect observed within 2 hours, maximal effect within 2-4 weeks of therapy.
Excretion
Approximately 35-50% of the absorbed dose is excreted in urine and the remainder via bile into feces.
Half life
Elimination half-life is approximately 13 hours.
Absorption
Rapidly and completely absorbed from the GI tract and converted to active olmesartan. Bioavailability is approximately 26%. Peak plasma concentrations occur 1-2 hours after an oral dose.
Metabolism
Olmesartan medoxomil is a prodrug; it is hydrolyzed to its active form, olmesartan, in the GI tract. Minimal further metabolism of olmesartan occurs.
Side Effects
Contraindications
- Hypersensitivity to olmesartan medoxomil or any component of the product.
- Pregnancy (especially during the second and third trimesters) due to risk of fetal harm.
- Bilateral renal artery stenosis.
- Concomitant use with aliskiren in patients with diabetes or moderate to severe renal impairment (GFR < 60 mL/min/1.73 m²).
- Severe hepatic impairment or biliary obstruction.
Drug Interactions
Lithium
Increased serum lithium concentrations and toxicity; monitor lithium levels carefully.
NSAIDs (Nonsteroidal Anti-inflammatory Drugs)
May reduce the antihypertensive effect of olmesartan and increase the risk of renal function deterioration.
Dual blockade of the RAS with ARBs, ACE inhibitors, or Aliskiren
Increased risk of hypotension, hyperkalemia, and changes in renal function (including acute renal failure).
Potassium-sparing diuretics, Potassium supplements, Salt substitutes containing potassium
May lead to increased serum potassium levels (hyperkalemia); monitor serum potassium.
Storage
Store below 30°C in a cool, dry place. Protect from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose include hypotension (low blood pressure) and possibly tachycardia (fast heartbeat) or bradycardia (slow heartbeat). Management involves symptomatic and supportive treatment. If ingestion is recent, induce vomiting or perform gastric lavage. Intravenous fluids may be administered to counteract hypotension.
Pregnancy & Lactation
Pregnancy: Contraindicated during the second and third trimesters due to potential for fetal injury and death. If pregnancy is detected, discontinue Olmesartan as soon as possible. Lactation: It is not known whether olmesartan is excreted in human milk, but a risk to the nursing infant cannot be excluded. A decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Side Effects
Contraindications
- Hypersensitivity to olmesartan medoxomil or any component of the product.
- Pregnancy (especially during the second and third trimesters) due to risk of fetal harm.
- Bilateral renal artery stenosis.
- Concomitant use with aliskiren in patients with diabetes or moderate to severe renal impairment (GFR < 60 mL/min/1.73 m²).
- Severe hepatic impairment or biliary obstruction.
Drug Interactions
Lithium
Increased serum lithium concentrations and toxicity; monitor lithium levels carefully.
NSAIDs (Nonsteroidal Anti-inflammatory Drugs)
May reduce the antihypertensive effect of olmesartan and increase the risk of renal function deterioration.
Dual blockade of the RAS with ARBs, ACE inhibitors, or Aliskiren
Increased risk of hypotension, hyperkalemia, and changes in renal function (including acute renal failure).
Potassium-sparing diuretics, Potassium supplements, Salt substitutes containing potassium
May lead to increased serum potassium levels (hyperkalemia); monitor serum potassium.
Storage
Store below 30°C in a cool, dry place. Protect from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose include hypotension (low blood pressure) and possibly tachycardia (fast heartbeat) or bradycardia (slow heartbeat). Management involves symptomatic and supportive treatment. If ingestion is recent, induce vomiting or perform gastric lavage. Intravenous fluids may be administered to counteract hypotension.
Pregnancy & Lactation
Pregnancy: Contraindicated during the second and third trimesters due to potential for fetal injury and death. If pregnancy is detected, discontinue Olmesartan as soon as possible. Lactation: It is not known whether olmesartan is excreted in human milk, but a risk to the nursing infant cannot be excluded. A decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2-3 years from the date of manufacture. Refer to the packaging for the exact expiry date.
Availability
Available in pharmacies and hospitals
Approval Status
Approved by DGDA (Bangladesh)
Patent Status
Off-patent in many countries
Clinical Trials
Extensive clinical trials have demonstrated the efficacy and safety of olmesartan medoxomil in lowering blood pressure and reducing the risk of cardiovascular events in hypertensive patients. Studies like the ROADMAP trial have also investigated its role in renal protection.
Lab Monitoring
- Serum creatinine and blood urea nitrogen (BUN) to monitor renal function, especially in patients with pre-existing renal impairment or those on high doses.
- Serum electrolytes (especially potassium) to monitor for hyperkalemia, particularly in patients receiving potassium supplements or diuretics.
Doctor Notes
- Advise patients about the importance of consistent medication adherence and regular blood pressure monitoring.
- Counsel on lifestyle modifications (diet, exercise, sodium restriction) to enhance therapeutic outcomes.
- Be vigilant for signs of hyperkalemia and renal function decline, especially in at-risk patients or those on concomitant medications that can affect potassium levels or renal function.
- Warn female patients of childbearing potential about the fetal risk and ensure appropriate contraception or alternative treatment if pregnancy is planned.
Patient Guidelines
- Take your medicine regularly at the same time each day, as directed by your doctor.
- Do not stop taking Olmesta without consulting your doctor, even if you feel well.
- Inform your doctor about all other medications you are taking, including over-the-counter drugs and herbal supplements.
- Monitor your blood pressure regularly at home and keep a record to show your doctor.
Missed Dose Advice
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one.
Driving Precautions
Olmesta may cause dizziness or fatigue in some individuals. If you experience these symptoms, avoid driving or operating machinery until you know how the medication affects you.
Lifestyle Advice
- Adopt a healthy diet low in sodium and saturated fats.
- Engage in regular physical activity, as advised by your doctor.
- Maintain a healthy weight.
- Limit alcohol consumption and avoid smoking.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Olmesta Brand
Other medicines available under the same brand name
